340B Hearing Underscores Era Of Oversight, But Rolling Back Discount Program Doesn’t Look Likely
This article was originally published in RPM Report
Executive Summary
A House Energy & Commerce/Health Subcommittee hearing on the 340B drug discount program suggests there is bipartisan interest in legislation to enhance oversight of the program – but little interest in steps that might dramatically curtail the availability of discounted drugs to hospitals and other safety net providers.